

Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity

NCT06967389

Status RECRUITING
Sponsor John Bauer
Enrollment 50 participants

Key Eligibility Criteria

Inclusion (3)

- Patient seen at University of Kentucky Pediatric High BMI Clinic
- Diagnosis of Obesity Class 2 or 3
- Meeting the clinical criteria for the medical intervention with semaglutide for weight loss

Exclusion (11)

- Any current prescribed anti-obesity medications (AOM) such as Orlistat, Phentermine, Qsymia (Phentermine/Topiramate), Liraglutide, Semaglutide, and Setmelanotide
 - Any current prescribed anti-hypertensive medications
 - Any specific end-organ acute concerns (kidney disease, liver disease, congenital disease).
 - Any active infections at enrollment.
 - Any systemic steroid use longer than 3 month use or within the last month before enrollment (not including inhaled, ophthalmic, intranasal, and topical).
- ... and 6 more (see full listing online)

Locations (1 total)

University of Kentucky, Lexington, Kentucky, United States